TD Cowen analyst Tyler Van Buren upgraded Summit Therapeutics plc (NASDAQ: SMMT) from to Buy.The analyst comments "Ivonescimab's exquisite engagement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE